Design and synthesis of novel 1-substituted -3-(4-oxo-2-phenylquinazolin-3(4H)-yl) urea and thiourea analogues targeting on TACE, as potent anticancer agents

Sandhya Dhokale; Snehal Thakar; Deepali Bansode

doi:10.30574/gscbps.2020.12.2.0255

Authors

Sandhya Dhokale Bharati Vidyapeeth (Deemed to be University), Poona College of Pharmacy, Kothrud, Pune-411038, Maharashtra, India.
Snehal Thakar Bharati Vidyapeeth (Deemed to be University), Poona College of Pharmacy, Kothrud, Pune-411038, Maharashtra, India.
Deepali Bansode Department of Pharmaceutical Chemistry, Bharati Vidyapeeth (Deemed to be University), Poona College of Pharmacy, Kothrud, Pune-411038, Maharashtra, India.

DOI:

https://doi.org/10.30574/gscbps.2020.12.2.0255

Keywords:

Anticancer, MDA-MB 231, MTT assay, Quinazolinone analogues, TACE

Abstract

1-substituted phenyl quinazolinones analogues were designed by performing molecular modelling studies against tumour necrosis factor alpha converting enzyme (TACE PDB Id: 2A8H) and in-silico Lipinski properties for drug likeness. From QSAR studies, it could be concluded that the urea and thiourea groups play a crucial role in enhancing cytotoxic effects of compounds. Substitution of halogens like trifluoromethyl, chloro and allylic functional group may enhance the cytotoxic effect of urea and thiourea analogues. Substitution of phenyl and benzoyl ring were not found effective against cancer. Also, the presence of substituted aromatic ring at position 3 and methyl or thiol group at position 2 are essential for antimicrobial activities of quinazolinone. The synthesized compounds were characterized by TLC, MP, IR, NMR and Mass spectral data and were screened for their anticancer activity. The in vitro anticancer studies were performed on six selected compounds using MTT assay against MDA MB-231 cell line using paclitaxel as a standard. The synthesized 1-substituted -3-(4-oxo-2-phenylquinazolin-3(4h)-yl) urea and thiourea derivatives exhibited significant anticancer activities.

Metrics

Metrics Loading ...

References

Rakesh KP, Darshini N, Shubhavathi T and Mallesha N. (2017). Biological applications of quinazolinone analogues: A review. Org Med Chem, 2(2), 1-5.

Kavitha K, Shrinivasan N and Haribabu Y. (2018) A review on quinazolinone and its derivatives with diverse biological activities. World J Pharm Pharm Sci, 7(4), 628–649.

Amol SJ and Sunil VA. (2017). Substituted quinazoline a potential drug candidate: an overview. World J Pharm Res, 6(15), 281-295.

El-Azab AS, Al-Omar MA, Alaa AM, Abdel-Aziz NI, Magda AA, Aleisa AM, Sayed-Ahmed MM and Abdel-Hamide SG. (2010). Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study. Eur J Med Chem, 45(9), 4188-4198.

World Health Organization. (2020).

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394–424.

KD Tripathi. (2013). Essentials of Medical Pharmacology. New Delhi, India Jaypee brother’s medical publishers (P) ltd.

Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J and Uchikawa O. (2014). Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach. J Med Chem, 57(21), 8886-8902.

Barlési F, Tchouhadjian C, Doddoli C, Villani P, Greillier L, Kleisbauer JP, Thomas P and Astoul P. (2005). Gefitinib (ZD1839, Iressa®) in non‐small‐cell lung cancer: a review of clinical trials from a daily practice perspective. Fundam Clin Pharmacol, 19(3) 385-393.

Ballard P, Bradbury RH, Harris CS, Hennequin LF, Hickinson M, Kettle JG, Kendrew J, Klinowska T, Ogilvie DJ, Pearson SE and Williams EJ. (2005). Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics. Bio Med Chem Lett, 16(18), 4908-4912.

Marzaro G, Guiotto A and Chilin A. (2012). Quinazoline derivatives as potential anticancer agents: a patent review (2007–2010). Expert Opin Ther Pat, 22(3), 223-252.

Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, Burkhart W, et al. (2002) The τumor necrosis factor- r converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry, 41(30), 9462-69.

Black RA. (2004). Tumor necrosis factor- a converting enzyme In. Handbook of Proteolytic Enzymes Aspartic and Metallo peptidase, 726- 729.

Abdel Gawad NM, Georgey HH, Youssef RM and El-Sayed NA. (2010). Synthesis and antitumor activity of some 2, 3-disubstituted quinazolin-4(3H)-ones and 4, 6- disubstituted- 1, 2, 3, 4-tetrahydroquinazolin- 2H-ones. Eur J Med Chem, 45(12), 6058–6067.

Ahmed MF and Youns M. (2013). Synthesis and biological evaluation of a novel series of 6, 8-dibromo-4(3H) quinazolinone derivatives as anticancer agents, Arch Pharm, 346(8), 610-617.

Noolvi M, Patel H, Bhardwaj V and Chauhan A. (2011). Synthesis and in-vitro anti-tumor activity of substituted quinazoline and quinoxaline derivatives: Search for anticancer agent. Eur J Med Chem, 46(6), 2327–2346.

Cao SL, Feng YP, Jiang YY, Liu SY, Ding GY and Li RT. (2005). Synthesis and in vitro antitumor activity of 4 (3H)-quinazolinone derivatives with dithiocarbamate side chains. Bioorganic Med Chem Lett, 15(7), 1915–1917.

Xia Y, Yang ZY, Hour MJ, Kuo SC, Xia P, Bastow KF, et al. (2011). Antitumor agents. Part 204: Synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioorganic Med Chem Lett, 11(9), 1193-1196.

Hurmath Unnissa S, Reddy GK and Aravazhi T. (2013). Synthesis and in Vitro anti-tumor activity of some novel 2, 3-disubstituted quinazolin 4(3H)-one derivatives. J Appl Pharm Sci, 3(10), 136–140.

Saeedi M, Mohammadi-Khanaposhtani M, Pourrabia P, Razzaghi N, Ghadimi R, Imanparast S, Faramarzi MA, Bandarian F, Esfahani EN, Safavi M and Rastegar H. (2019). Design and synthesis of novel quinazolinone-1, 2, 3-triazole hybrids as new anti-diabetic agents: In vitro α-glucosidase inhibition, kinetic, and docking study. Bioorganic chemistry, 83, 161-9.

Dahiya R, Kumar A and Yadav R. (2008). Synthesis and Biological Activity of Peptide Derivatives of Iodoquinazolinones/Nitroimidazoles. Molecules, 13(3), 958–76.

Rajveer CH and Kumaraswamy SR. (2010). Synthesis of some 6-bromo quinazolinone derivatives for their pharmacological activities. Int J Pharm Bio, 6(2), 50-56.

Dhokale SR, Thakar SR, Bansode DA and Mahadik KR. (2019). Synthesis, screening of novel 1-substituted-3- (4-oxo-2-phenylquinazolin- 3 (4H) -yl) urea and thiourea analogues as potent antibacterials. Int J Pharm Pharm Sci, 11(11), 38-42.

Furniss BS, Hannaford AJ, Smith PWG and Tatchell AR. (1998). Vogel’s textbook of practical organic chemistry. United Kingdom, Pearson education Limited.

Messali M, Aouad MR, Ali AA, Rezki N, Hadda TB and Hammouti B. (2015). Synthesis, characterization, and POM analysis of novel bioactive imidazolium-based ionic liquids. Med Chem Res, 24, 1387-1395.

Pavia D, Lampmanh H and Kvizgeorge. (2017). Introduction to Spectroscopy, Boston UK, Cengage Learning.

Wani KD, Kitture R, Ahmed A, Choudhari AS, Koppikar SJ, Kale SN and Kaul-Ghanekar R. (2011). Synthesis, characterization and in vitro study of curcumin-functionalized citric acid-capped magnetic (CCF) nanoparticles as drug delivery agents in cancer. J Bionano, 5(1), 59-65.

Saravanan G, Alagarsamy V and Prakash CR. (2015). Synthesis, characterization and in vitro antimicrobial activity of some 1-(substitutedbenzylidene)-4-(4-(2-(methyl/phenyl)-4-oxoquinazolin-3 (4H)-yl) phenyl) semicarbazide derivatives. J Saudi Chem Soc, 19(9), 3-11.

Eweas AF, El-Nezhawy AO, Baiuomy AR and Awad MM. (2012). Design, synthesis, anti-inflammatory, analgesic screening, and molecular docking of some novel 2-pyridyl (3H)-quinazolin-4-one derivatives. Med Chem Res, 22, 1011-20..